This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2018 Apr 10;319(14):1431-1432.

doi: 10.1001/jama.2018.0345.

Novel Vaccine Technologies: Essential Components of an Adequate Response to Emerging Viral Diseases

Barney S Graham¹, John R Mascola¹, Anthony S Fauci²

Affiliations

Affiliations

¹ Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
² Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.

PMID: 29566112
DOI: 10.1001/jama.2018.0345

Novel Vaccine Technologies: Essential Components of an Adequate Response to Emerging Viral Diseases

Barney S Graham et al. JAMA. 2018.

. 2018 Apr 10;319(14):1431-1432.

doi: 10.1001/jama.2018.0345.

Authors

Barney S Graham¹, John R Mascola¹, Anthony S Fauci²

Affiliations

¹ Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
² Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.

PMID: 29566112
DOI: 10.1001/jama.2018.0345

No abstract available

PubMed Disclaimer

Similar articles

Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.
Barrett PN, Terpening SJ, Snow D, Cobb RR, Kistner O. Barrett PN, et al. Expert Rev Vaccines. 2017 Sep;16(9):883-894. doi: 10.1080/14760584.2017.1357471. Epub 2017 Jul 27. Expert Rev Vaccines. 2017. PMID: 28724343 Review.
[Emerging viral diseases in Europe].
Löbermann M, Gürtler LG, Eichler-Löbermann B, Reisinger EC. Löbermann M, et al. Dtsch Med Wochenschr. 2012 Apr;137(17):900-5. doi: 10.1055/s-0032-1304932. Epub 2012 Apr 17. Dtsch Med Wochenschr. 2012. PMID: 22511281 Review. German.
Adventitious agents and vaccines.
Krause PR. Krause PR. Emerg Infect Dis. 2001;7(3 Suppl):562. doi: 10.3201/eid0707.017735. Emerg Infect Dis. 2001. PMID: 11485673 Free PMC article. No abstract available.
Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic.
Graham BS, Sullivan NJ. Graham BS, et al. Nat Immunol. 2018 Jan;19(1):20-28. doi: 10.1038/s41590-017-0007-9. Epub 2017 Dec 14. Nat Immunol. 2018. PMID: 29199281 Free PMC article. Review.
DNA vaccines: a safe and efficient platform technology for responding to emerging infectious diseases.
Ledgerwood JE, Graham BS. Ledgerwood JE, et al. Hum Vaccin. 2009 Sep;5(9):623-6. doi: 10.4161/hv.8627. Hum Vaccin. 2009. PMID: 19779298 Review. No abstract available.

See all similar articles

Cited by

Live-attenuated virus vaccine defective in RNAi suppression induces rapid protection in neonatal and adult mice lacking mature B and T cells.
Chen G, Han Q, Li WX, Hai R, Ding SW. Chen G, et al. Proc Natl Acad Sci U S A. 2024 Apr 23;121(17):e2321170121. doi: 10.1073/pnas.2321170121. Epub 2024 Apr 17. Proc Natl Acad Sci U S A. 2024. PMID: 38630724 Free PMC article.
Clinical Analysis and Applications of mRNA Vaccines in Infectious Diseases and Cancer Treatment.
Ankrah PK, Ilesanmi A, Akinyemi AO, Lasehinde V, Adurosakin OE, Ajayi OH. Ankrah PK, et al. Cureus. 2023 Oct 2;15(10):e46354. doi: 10.7759/cureus.46354. eCollection 2023 Oct. Cureus. 2023. PMID: 37920621 Free PMC article. Review.
THE GORDON WILSON LECTURE: RAPID COVID-19 VACCINE DEVELOPMENT AND THE FUTURE OF VACCINOLOGY.
Graham BS. Graham BS. Trans Am Clin Climatol Assoc. 2023;133:103-105. Trans Am Clin Climatol Assoc. 2023. PMID: 37701620 Free PMC article. No abstract available.
Potential use of the S-protein-Angiotensin converting enzyme 2 binding pathway in the treatment of coronavirus disease 2019.
Feng L, Fu S, Zhang P, Zhang Y, Zhao Y, Yao Y, Luo L, Ping P. Feng L, et al. Front Public Health. 2022 Nov 28;10:1050034. doi: 10.3389/fpubh.2022.1050034. eCollection 2022. Front Public Health. 2022. PMID: 36518573 Free PMC article. Review.
A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes.
Arevalo CP, Bolton MJ, Le Sage V, Ye N, Furey C, Muramatsu H, Alameh MG, Pardi N, Drapeau EM, Parkhouse K, Garretson T, Morris JS, Moncla LH, Tam YK, Fan SHY, Lakdawala SS, Weissman D, Hensley SE. Arevalo CP, et al. Science. 2022 Nov 25;378(6622):899-904. doi: 10.1126/science.abm0271. Epub 2022 Nov 24. Science. 2022. PMID: 36423275 Free PMC article.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information